May 20, 2024

Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide

Key Points

Key points are not available for this paper at this time.

Abstract

To describe overall survival, time to castration resistance and castration resistance-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide in a US oncology network.

اسأل الذكاء الاصطناعي

Bookmark

Cite This Study

Lowentritt et al. (Mon,) studied this question.

synapsesocial.com/papers/68e69377b6db64358761aa37 https://doi.org/https://doi.org/10.1080/14796694.2024.2343647

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.2023 · 4 citations
2Cancer statistics, 20232023 · 16,679 citations
3MP29-14 PROSTATE-SPECIFIC ANTIGEN RESPONSE AND TIME-TO-CASTRATION RESISTANCE AMONG PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER INITIATED ON APALUTAMIDE, ENZALUTAMIDE, OR ABIRATERONE ACETATE2023 · 1 citations
4FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer2018 · 11 citations
5Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth2008 · 1,413 citations

اسأل الذكاء الاصطناعي

Bookmark